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Anti-apoptosis17β-Estradiol can promote the growth and development of several estrogen receptor (ER)-negative breast
cancers. The effects are rapid and non-genomic, suggesting that a membrane-associated ER is involved. ERα36
has been shown to mediate rapid, non-genomic, membrane-associated effects of 17β-estradiol in several cancer
cell lines, including triple negative HCC38 breast cancer cells. Moreover, the effect is anti-apoptotic. The aim of
this study was to determine if ERα36 mediates this anti-apoptotic effect, and to elucidate the mechanism
involved. Taxol was used to induce apoptosis in HCC38 cells, and the effect of 17β-estradiol pre-treatment was
determined. Antibodies to ERα36, signal pathway inhibitors, ERα36 deletion mutants, and ERα36-silencing
were used prior to these treatments to determine the role of ERα36 in these effects and to determine which
signalingmolecules were involved.We found that the anti-apoptotic effect of 17β-estradiol inHCC38 breast can-
cer cells is in factmediated bymembrane-associated ERα36.We also showed that this signaling occurs through a
pathway that requires PLD, LPA, and PI3K; Gαs and calcium signalingmay also be involved. In addition, dynamic
palmitoylation is required for the membrane-associated effect of 17β-estradiol. Exon 9 of ERα36, a unique exon
to ERα36 not found in other identiﬁed splice variants of ERαwith previously unknown function, is necessary for
these effects. This study provides a working model for a mechanism bywhich estradiol promotes anti-apoptosis
through membrane-associated ERα36, suggesting that ERα36 may be a potential membrane target for drug
design against breast cancer, particularly triple negative breast cancer.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Although the 5-year survival for patients diagnosed in the early
stages of breast cancer exceeds 90%, survival in patients with distant
metastasis drops below 25% indicating very poor prognosis for these
individuals [1]. While an actual cure for breast cancer is elusive, novel
approaches to diagnosis and treatment can help to reduce mortality
and allow patients, speciﬁcally those with more advanced stage cancer,
to live normal lives.
The progression of cancer is a dynamic process that begins with pri-
mary tumor growth, depending on cancer cell proliferation simulta-
neously with the ability of cancer cells to evade apoptosis [2]. In some
cases, aggressive cancer cells can evade apoptosis even in the presence
of radiotherapy and chemotherapeutic drugs that are used to target
these cells and speciﬁcally induce apoptosis [3,4]. Current approachesinia Commonwealth University,
3284-3068, USA. Tel.: +1 804to treatment have evolved to combination therapy, usually beginning
with surgery and/or targeted radiotherapy, followed by adjunctive
chemotherapy [5–7]. Taxol, a commonly used chemotherapeutic drug,
induces apoptosis in cells by inhibiting mitosis [8,9]. Currently, taxol is
synthetically prepared and various formulations and carriers are being
developed to increase the effectiveness of the drug [10]. Moreover, the
main problem with drugs such as taxol is that they do not only target
cancer cells, but can also induce apoptosis in normal cells [11,12]. This
necessitates current approaches of targeted therapy, by which newer
targets are being discovered that are either unique or highly upregulated
in cancer cells.
Estrogen receptors (ERs) play a major role in classiﬁcation,
diagnosis, and treatment of breast cancer [13–15]. Patients who have
hormone responsive or ER-positive tumors are expected to take the
ER-antagonist tamoxifen continuously for 10 years following initial
treatment [16]. We previously showed that tamoxifen could block the
stimulatory effect of 17b-estradiol (E2) in not only ER-positive breast
cancer cells but also ER-negative breast cancer cells [17]. Traditional
inhibitors of ERs, such as ICI 182,780, and diethylsilbesterol, a potent
synthetic agonist for ERα, did not block E2-induced cell proliferation
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tional antibodies to ERα and ERβ [17].
Membrane-associated E2 signaling also elicits anti-apoptotic effects
against taxol, leading to an aggressive cancer phenotype [3,18]. We re-
cently showed that ERα36, an alternatively spliced variant to traditional
ERα, is responsible for the membrane-mediated effect of E2 in breast
cancer cells that promotes cell survivability [18,19]. The mRNA of
ERα36 lacks the ﬁrst exon found in traditional ERα, ERα66, as well as
exons 7 and 8 [20]. This results in a truncated form of ERα that does
not contain the transcriptional activation domains AF1 or AF2 and a
truncated ligand-binding domain; however, ERα36 still exhibits
ligand-dependent effects of E2 [20–22]. In addition, ERα36 contains a
novel exon at the C-terminus known as exon 9. This exon contains 27
amino acids of unknown function, but it is hypothesized to contain
myristoylation or palmitoylation-speciﬁc sequences [20,23], which
would help to explain any membrane-associated effects mediated by
ERα36. This study investigated a mechanism by which ERα36 prevents
taxol-induced apoptosis. We hypothesized that ligand-dependent
activation of ERα36 induces receptor-dependent inhibition of signaling
cascades associated with anti-apoptosis.
2. Materials and methods
2.1. Reagents
Triple negative HCC38 human breast cancer cells, which we previ-
ously showed to also be negative for the ERα splice variants, ERα66
and ERα46, but positive for ERα36 [18], and human embryonic kidney
HEK293 cells were obtained from the American Type Culture Collection
(ATCC, Manassas, VA). Roswell Park Memorial Institute 1640 medium
(RPMI 1640) and Dulbecco's modiﬁed Eagle's medium (DMEM) were
purchased from Invitrogen (Grand Island, NY). Charcoal/dextran-
ﬁltered fetal bovine serum (FBS) was purchased from Gemini
Bioproducts (Sacramento, CA). E2 enantiomer (Ent-E2) was kindly pro-
vided as a gift fromDr. Douglas Covey (WashingtonUniversity, St. Louis,
MO) and has been described previously [24]. E2, E2-BSA, taxol, 2-
hydroxymyristic acid (HMA), 2-bromohexadecanoic acid (2-
bromopalmitate, 2-BP), and tunicamycin (Tm) were purchased from
Sigma (St. Louis, MO). Cycloheximide (CHM), wortmannin, D609,
U73122, LY294002, thapsigargin, pertussis toxin (PTX), and cholera
toxin (CTX) were purchased from EMD Chemicals (Gibbstown, NJ).
VPC32183S and lysophosphatidic acid (LPA) were purchased from
Avanti Polar Lipids (Alabaster, AL). Protein content of samples was
measured using theMacro BCA reagent kit fromPierce/Thermo Scientiﬁc
(Rockford, IL). Polyclonal ERα36 antibodies against the unique
C-terminal 27 amino acids were generated by Cell Applications Inc.
(San Diego, CA). A monoclonal anti-ERα antibody that recognizes the
three ERα splice variants ERα66, ERα46, and ERα36 was purchased
from Abcam (San Francisco, CA). 740 Y-P and the Titertacs TUNEL
assay were purchased from R&D Systems (Minneapolis, MN). Goat
anti-rabbit horseradish peroxidase (HRP) and goat anti-mouse HRP-
conjugated secondary antibodies were obtained from Bio-Rad (Hercules,
CA). Bax and Bcl2 primers were purchased from Euroﬁns MWG Operon
(Huntsville, AL). The cytochrome C apoptosis assay kit was purchased
from MBL International (Woburn, MA). The Amplex Red Phospholipase
D (PLD) Assay kit was purchased from Life Technologies (Grand Island,
NY). Caspase-3 activity was measured using the CaspAce Assay system
from Promega (Madison, WI). ERα36 overexpression plasmids were
purchased from Chi Scientiﬁc (Maynard, MA). Polyfect transfection
reagent was obtained from Qiagen (Germantown, MD).
2.2. Cell culture
HCC38 cells and HEK293 cells were cultured in RPMI 1640-based
media or DMEM, respectively, as speciﬁed by the ATCC containing
10% charcoal/dextran-ﬁltered FBS and lacking phenol red, which canmimic the effects of E2 at low levels [25,26]. Speciﬁc modiﬁcations for
each experimental question are described below. For all experimental
treatments, the solvent used according to preparation instructions by
the manufacturer of each reagent was used in equivalent amounts as a
treatment vehicle in all controls.
2.3. Apoptotic effect of taxol in HCC38 cells
The experimental design for this studywas based on the ability of E2
to block the apoptotic effects of taxol. Initial experiments were per-
formed to establish the effect of taxol on HCC38 cells. 24 h after plating,
HCC38 cells were treated with increasing concentrations of taxol (5, 10,
20 μM) for 4 h, after which caspase-3 activity was measured using an
assay kit from Promega according to the manufacturer's directions. To
conﬁrm that the effects of taxol were apoptotic, as caspase-3 activity
is implicated in the terminal differentiation of some cell types [27–30],
HCC38 cells were treated with 20 μM taxol for 12 h, after which BAX/
BCL2 mRNA levels were determined and cytochrome C translocation
from themitochondria to the cytosol was examined by the cytochrome
C apoptosis assay kit from MBL International according to the
manufacturer's instructions. In addition, 24 h after treatment with
taxol, apoptosis-associated DNA-fragmentation was determined
using a TUNEL assay kit as per the manufacturer's directions.
2.4. Requirement for a receptor-mediated membrane-associated mechanism
E2 conjugated to bovine serum albumin (E2-BSA), which cannot
cross the plasma membrane (PM) [31–33], was used to verify that the
anti-apoptotic effect of E2 was via a membrane-mediated mechanism.
E2-BSA has previously been shown to have similar effects to E2 and
can interact with ERs. BSA conjugation prevents E2 from crossing the
PM, and therefore, E2-BSA effects can be attributed to either membrane
receptor effects or alterations in membrane ﬂuidity due to the hydro-
phobic nature of E2-BSA [17,31,32,34]. To address the possibility that
E2's effect is due to a non-speciﬁc interaction with the PM, cells were
also treated with the E2 enantiomer, Ent-E2 [24]. While Ent-E2 has
the same chemical structure as E2 as its enantiomer, it cannot directly
interact with ERs, and therefore, any effects caused by Ent-E2 could be
attributed to its direct effect on membrane ﬂuidity, as it possesses the
same hydrophobic properties of E2.
PLD activity was determined as an outcome measure, based on our
previous observation that the anti-apoptotic effect of the vitamin
D3 metabolite 24R,25-dihydroxyvitamin-D3 (24,25(OH)2D3) occurs
through activation of PLD [35]. Subconﬂuent cultures of HCC38 cells in
24-well tissue culture polystyrene (TCPS) plates were treated with E2
or Ent-E2. Also, prior to E2 treatment, a 15 minute pretreatment of
cells with polyclonal ERα36 speciﬁc antibodies (1:500 dilution) was
performed to block the membrane receptor in order to determine if
the effect of E2 was through membrane-associated ERα36. While anti-
bodies cannot enter the cells, any inhibition of E2's effect in the presence
of antibody could be attributed to E2's direct interaction with
membrane-associated ERα36. Following the 15 minute antibody pre-
treatment, and a 30 minute E2 treatment, samples were harvested
and assayed for PLD activity using the Amplex Red PLD assay from Life
Technologies according to the manufacturer's instructions.
2.5. ERα36 silencing, overexpression, and mutation
In order to conﬁrm the role of ERα36 in the anti-apoptotic effect of E2,
HCC38 cells were transiently transfected with an ERα36 shRNA expres-
sion plasmid in order to transiently knockdown ERα36. The shRNA
expression plasmid was produced by cloning a microRNA speciﬁc anti-
sense target sequence for the 3′UTR of ERα36 cDNA using the DNA oligo-
nucleotides, 5′-GGATCCCATGCCAATAGGTACTGAATTGATATCCGTTCAGT
ACCTATTGGCATTTTTTTCCAAAAGCTT-3′, and was prepared by Sigma-
Aldrich using their Mission shRNA puriﬁed plasmid expression system.
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ture treated polystyrene (TCPS) and cultured in media containing no an-
tibiotics. One day after plating, when cells were approximately 75%
conﬂuent, transient transfection was performed using Polyfect transfec-
tion reagent from Qiagen according to the manufacturer's instructions.
Mediawere changed after 24 h to full growthmedia, and 48 h after trans-
fection, cells were treated according to experimental procedures. The PLD
and caspase-3 activity assays were performed with HCC38 silenced for
ERα36 (denoted as shERα36), wildtype HCC38 cells (denoted as WT),
and non-target transfected HCC38 cells (denoted as shControl). Whole
cell lysates were harvested in RIPA and western blot was performed on
WT, shControl, and shERα36 HCC38 cells using ERα36 antibodies
(1:500 dilution). Densitometry analysis using Quantity One software
was performed to determine percentage of knockdown in shERα36 cells.
In order to determine the importance of ERα36on amore generalized
platform, the human embryonic kidney cell line, HEK293,which has been
previously cited to not express functional levels of endogenous ERα36
[21], was used as a model for analysis of wildtype exogenous ERα36
overexpression (denoted as 293ovrx36). Use of HEK293 cells thus
allowed us to examine the role ofwildtype exogenous ERα36 andmutat-
ed ERα36 independent of the presence of functional endogenous ERα36.
Because exon 9 is unique to ERα36, and ERα66 has not been shown
to mediate the membrane-associated effect of E2 in ER-positive MCF7
cells [17], we hypothesized that exon 9was required for these responses.
An exon 9 deletion mutant (denoted as 293ex9d36) was created using
overlap extension PCR cloning as previously described by Bryksin and
Matsumura [36]. Exon 9 deleted HEK293 cells were then created accord-
ing to the methods described below, allowing us to examine the require-
ment of this exon in the anti-apoptotic pathway of E2.
HEK293 cells were transiently transfected with ERα36 full-length
wildtype cDNA and ERα36 exon 9-deletion cDNA plasmids using
Polyfect transfection reagent according to the manufacturer's instruc-
tions. HEK293 cells were seeded at a density of 1.25 × 105 cells/cm2 in
TCPS plates and cultured in medium containing no antibiotics. One
day after plating, when cells were approximately 75% conﬂuent, tran-
sient transfection was performed using Polyfect transfection reagent
according to the manufacturer's protocol. Media were changed after
24 h to full growthmedia, and 48 h after transfection, cells were treated
as previously described for measurement of PLD and caspase-3 activity.
PLD and caspase-3 activity assays were performed in HEK293 over-
expressed with wildtype ERα36 (293ovrx36) and exon 9-deleted
ERα36 (293ex9d26). Wildtype HEK293 cells mock transfected with a
non-targeting vector and plated at the same time as the mutant cells
were used as positive controls. Whole cell lysates were harvested in
RIPA and western blot was performed on 293wt, 293ovrx36, and
293ex9d36 HEK293 cells using ERα antibodies (1:500 dilution) that
can also detect ERα36. These antibodies were used rather than ERα36
antibodies because the ERα36 antibodies detect the C-terminal domain
of ERα36, and the exon 9 deletionmutants (293ex9d36) do not contain
this region. Bands shown in western blots were detected at ~36 kDa.
Densitometry analysis using Quantity One software was performed to
determine percentage of knockdown in shERα36 cells.
2.6. Examination of E2's anti-apoptotic pathway
In order to determine the signaling pathway involved in the anti-
apoptotic effect of E2, we took advantage of the observation that E2
inhibits taxol-induced apoptosis via membrane-associated signaling
by attenuating the effect of taxol on caspase-3 activity [3,18]. For the ex-
periments described below, subconﬂuent cultures of HCC38 cells were
pretreated with 10−8 M E2 for 90 min followed by 20 μM taxol treat-
ment, after which time, E2 was removed from the cultures. After 24 h
of taxol treatment, the number of viable cells was determined by the
MTT assay, which measures the reduction of 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide to purple formazan by
mitochondrial reductase in living cells [37]. After 4 h of taxoltreatment, caspase-3 activity was determined as described above.
Requirement for ERα36 was determined by pretreating the
HCC38 cells with antibodies generated against the unique C-
terminus of ERα36. Phosphatidylcholine-speciﬁc PLD (PC-PLD) was
inhibited using 10−5 M wortmannin [38,39]. Phosphatidylcholine-
speciﬁc phospholipase C (PC-PLC) was inhibited using 5 × 10−5 M
D609 [39,40]. Phosphatidylinositol-speciﬁc phospholipase C (PI-PLC)
was inhibited using 10−5 M U73122 [38,39]. 10−6 M VPC32183S was
used to block lysophosphatidic acid (LPA) signaling through LPA1 and
LPA3 receptors, while LPA was used to activate LPA signaling [35].
10−5 M LY294002 was used to block phosphoinositide-3-kinase
(PI3K) [35]. 10−6 M 740 Y-P was used to activate PI3K signaling
[41]. 3 μM thapsigargin was used to inhibit calcium translocation
from the rough endoplasmic reticulum to the cytosol. Pertussis
toxin (25 ng/mL) was used to inhibit Gαi signaling, while cholera toxin
(100 ng/mL) was used to inhibit Gαs signaling [35]. E2-BSA was also
used in several of these experiments to further determine if these effects
weremembrane-associated. As previously described, E2-BSA cannot cross
the PM, but still has many similar effects to E2. For all caspase-3 experi-
ments using E2-BSA, subconﬂuent cultures ofHCC38 cellswere pretreated
as with the inhibitors stated above followed with 10−8 M E2-BSA for
90 min. 20 μM taxol was then added, and after 4 h of taxol treatment,
caspase-3 activity was measured as described above.
2.7. Requirement for dynamic palmitoylation
Previous work has shown that ERs, particularly the ERα variants
ERα66 and ERα46, can be targeted to the PM by palmitoylation [42,43].
ERα66 and ERα46 have been identiﬁed as translocating to the PM
due to palmitoylation. In order to examine this, tunicamycin and
2-bromohexadecanoic acid (2-bromopalmitate, 2-BP) were used to in-
hibit palmitoylacetyl-transferase and thus prevent palmitoylation of
ERα36 [42]. Cycloheximide (8 μM), an inhibitor of protein synthesis,
was used to disrupt N-glycosylation and HMA (0.5 mM) was used to
block myristoylation [42]. HCC38 cells were pre-treated with 30 μM
tunicamycin (Tm) and 10 μM 2-BP to inhibit the activity of
palmitoylacetyltransferase, which is responsible for post-translational
palmitoylation of proteins that are targeted to the PM [42,44].
Tunicamycin, however, also inhibits N-linked glycosylation [42],
and because of this, we also pre-treated cells with 8 μM cycloheximide
(CHM) as a control for N-glycosylation inhibition [42]. In order to invali-
date the possibility that the membrane effects of E2 through ERα36 do
not occur due to myristoylation, we also pre-treated cells with 0.5 mM
2-hydroxymyristic acid (HMA), which blocks post-translational
myristoylation [42]. In order to determine if palmitoylation of ERα36
is necessary for the anti-apoptotic effect of E2, HCC38 cells were pre-
treated with 30 μM Tm and 10 μM 2-BP for 2 h prior to E2 and taxol
treatment for 4 h, after which, caspase-3 activity was measured.
2.8. Statistical analyses
For all experiments, statistical analyses were performed by analysis
of variance with Bonferroni's correction for multiple comparisons.
All experiments were performed with n = 6 individual cultures per
variable, enabling statistical analysis for individual experiments. Exper-
iments were performed multiple times to ensure validity of the data.
Results of individual experiments are presented. For all graphs, error
bars represent standard error of the mean of 6 individual cultures per
variable in one representative experiment.
3. Results
3.1. Effect of taxol on apoptosis
Taxol induced apoptosis in the HCC38 cells. Terminal deoxynuc-
leotidyl transferase dUTP nick-end labeling (TUNEL) and caspase-3
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also increased, conﬁrming that the cellswere apoptotic (Fig. 1C). Results
were further conﬁrmed by an increase in cytochrome C translocation
from the mitochondria to the cytosol in the presence of 20 μM taxol
(Fig. 1D).
3.2. Role of ERα36 in activation of PLD by E2
We found that 10−8M E2 activated phospholipase D (PLD) in HCC38
cells at 30 and 60 min (Fig. 2A). The effect was receptor-mediated.
Unlike E2, E2 enantiomer (Ent-E2) concentrations used in this study
did not have the same effect at 30 min (Fig. 2B). Antibodies to ERα36
blocked the effect of E2 on PLD activity (Fig. 2C). Additionally, when
HCC38 cells were transiently transfectedwith ERα36 shRNA expression
plasmids (Fig. 2D) resulting in greater than 70% knockdown of ERα36
protein levels, E2 was unable to increase PLD activity (Fig. 2E).
3.3. Role of ERα36 in the anti-apoptotic effect of E2
Membrane activation of ERα36 signaling by E2 caused the anti-
apoptotic effect of E2 against taxol. E2 blocked taxol-induced effects on
MTT and caspase-3 activation while the antibody to ERα36 prevented
the effect of E2 (Fig. 2F,G) and E2 conjugated to bovine serum albumin
(E2-BSA) (Fig. 2H). Additionally, HCC38 cells transiently transfected
with ERα36 shRNA expression plasmids (Fig. 2D) exhibited a reduced
ability of E2 to block taxol-induced caspase-3 activity (Fig. 2I).
3.4. Role of exon 9
HEK293 cells transiently transfected with wildtype ERα36 cDNA
expression vectors and mutant vectors designed to express exonFig. 1. Effect of taxol on apoptosis in HCC38 cells. (A) Taxol's (0, 5, 10, 20 μM) effect on TUNEL
(C) Taxol also increased bax/bcl2mRNA levels (12 h post-treatment) and (D) cytochrome C lev
control group while # represents p b 0.05 compared to 5 μM taxol.9-deleted ERα36 cDNA were shown to have greater detectable levels
of ERα36 protein compared to wildtype HEK293 cells, which exhibited
very low levels of ERα36 shown by western blot using ERα antibodies
that detect ERα36 (Fig. 3A). Although wildtype HEK293 cells exhibited
decreased PLD activity after 30min of treatmentwith 10−8ME2, HEK293
cells transiently overexpressing exogenous wildtype ERα36 (293ovrx36)
exhibited increased PLD activity after 30 min of E2 treatment. Exon 9-
deleted exogenous ERα36 expressionmutants (293ex9d36)were unable
to promote this effect of E2 on PLD activity (Fig. 3B). Additionally, while
overexpression of wildtype ERα36 allowed E2 to block taxol-induced
caspase-3 activity inHEK293 cells, exon 9deletion did not appear to affect
E2's effect against taxol induced caspase-3 activity. Interestingly, exon 9
deletion increased caspase-3 activity alone (Fig. 3C).
3.5. Role of PLD
We also found that inhibition of phosphatidylcholine speciﬁc PLD
(PC-PLD) with wortmannin blocked the anti-apoptotic effect of E2 on
taxol-induced caspase-3 activity (Fig. 4A), indicating that the effect of
E2 on PLD leads to its anti-apoptotic effect. We did not see a similar
effect when we inhibited phosphatidylcholine speciﬁc phospholipase
C (PC-PLC) with D609 (Fig. 4B) or phosphatidylinositol speciﬁc PLC
(PI-PLC) with U73122 (Fig. 4C), nor in the case of E2-BSA's effect on
taxol-induced caspase-3 activity (Supplementary Figs. S1 and S2,
respectively).
3.6. Role of lysophosphatidic acid
The anti-apoptotic pathway of E2 wasmediated by lysophosphatidic
acid (LPA) signaling. When LPA signaling through the LPA1/3 receptors
was inhibited with VPC32183S, the anti-apoptotic effect of E2 and(24 h post-treatment) and (B) caspase-3 activity (4 h post-treatment) is dose-dependent.
els in the cytosol versus themitochondria. * represents p b 0.05 compared to the untreated
Fig. 2. Role of ERα36 in the effect of E2 on phospholipase D activity and anti-apoptosis. (A) Time course study of the effect of E2 on PLD activity in HCC38 cells. (B) Dose dependent effect of
E2 on PLD activity after 30min inHCC38 cells. Ent-E2 showed no ability to enhance PLD at any concentration. (C) Pre-incubationwith anti-ERα36 antibodies for 15min inhibited the effect
of a 30 minute 10−8 M E2 treatment on PLD activity. (D) Using anti-ERα36 antibodies, western blot was performed on whole cell lysates from HCC38 cells transiently transfected with a
non-target control shRNA vector (shControl), non-transfected wildtype HCC38 cells (WT), and HCC38 cells transiently transfected with ERα36 shRNA vector (shERα36). Densitometry
analysis showed greater than 70% knockdown of ERα36 protein levels in the shERα36 cells compared to wildtype controls. All samples were normalized to GAPDH. (E) Transient trans-
fection of HCC38 cells with ERα36 shRNA expression plasmid blocks the effect of E2 on PLD activity after 30 min. * represents p b 0.05 compared to the corresponding untreated control
group while # represents p b 0.05 compared to E2-treatment. (F) MTT is reduced by 20 μM taxol, while this effect is prevented by 10−8 M E2. ERα36 antibodies block this effect of E2.
(G) Taxol-induced (20 μM) caspase-3 activity is reduced by 10−8 M E2, while ERα36 antibodies block this effect. (H) Taxol-induced (20 μM) caspase-3 activity is reduced by 10−8 M
E2-BSA, while ERα36 antibodies block this effect. (I) While E2 inhibits taxol-induced caspase-3 activity in wildtype HCC38 cells, HCC38 cells transiently transfected with shERα36
expression plasmids did not show the same effect. * represents p b 0.05 compared to the untreated control group while # represents p b 0.05 compared to 20 μM taxol and $ represents
p b 0.05 compared to anti-ERα36 or shERα36 alone.
2800 R.A. Chaudhri et al. / Biochimica et Biophysica Acta 1843 (2014) 2796–2806E2-BSA on taxol-induced caspase-3 activity was prevented (Fig. 5A,
Supplementary Fig. S3). VPC32183S also inhibited the effect of
taxol (Fig. 5A), suggesting some crosstalk in the taxol and E2
pathways. LPA blocked the effect of taxol on caspase-3 activity in a
similar manner as E2 (Fig. 5B).3.7. Role of phosphoinositide-3-kinase
Phosphoinositide-3-kinase (PI3K) plays a role in the anti-apoptotic
pathway of E2. Inhibition of PI3K with LY294002 prevented the
effect of E2 and E2-BSA on taxol-induced caspase-3 activity (Fig. 5C,Supplementary Fig. S4). Conversely, the PI3K activator 740 Y-P
prevented taxol-induced caspase-3 activity (Fig. 5D).3.8. Effect of calcium and g-protein signaling
Pre-treatment of cells with thapsigargin, which inhibits cytosolic
calcium inﬂux from the endoplasmic reticulum, increased caspase-3
activity to a comparable extent as taxol, indicating that blocking of calci-
um signaling can induce apoptosis (Fig. 5E,F). E2 alone cannot overcome
the effect of thapsigargin on caspase-3 activity (Supplementary Fig. S6).
E2 or E2-BSA (Supplementary Fig. S7) reversed this effect. Pertussis toxin
Fig. 3. Requirement of exon 9 in the anti-apoptotic effect of E2. (A) Using a single monoclonal anti-ERα antibody from Abcam that recognizes all three splice variants, ERα66, ERα46, and
ERα36, western blots were performed onwhole cell lysates fromwildtype HEK293 cells (293wt), and HEK293 transiently transfected to overexpress wildtype ERα36 cDNA (293ovrx36)
and exon 9-deleted ERα36 cDNA (293ex9d36). (B) PLD activity is reduced with 10−8 M E2 wildtype HEK293 cells, while E2 increases PLD activity in ERα36 overexpressed HEK293 cells.
In cells overexpressing exon 9-deleted ERα36, E2 did not exhibit this effect. * represents p b 0.05 compared to the corresponding untreated control group. (C) ERα36 overexpression
mediated the anti-apoptotic effect of E2 against taxol-induced caspase-3 activity, but in cells with exon 9-deleted ERα36, this effect was not evident. * represents p b 0.05 compared to
the corresponding untreated 293wt, # represents p b 0.05 compared to taxol only in 293wt, $ represents p b 0.05 compared to untreated 293ovrx36, and @ represents p b 0.05 compared
to taxol only in 293ovrx36.
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did cholera toxin (CTX),which inhibits Gαs signaling (Fig. 5F). Neither E2
nor E2-BSA had an effect on PTX-induced caspase-3 activity; however,Fig. 4. Role of phospholipases in the anti-apoptotic effect of E2 in HCC38 cells. (A) Taxol-induced
(B) D609 and (C) U73122 do not exhibit the same effect as wortmannin. * represents p b 0.05
taxol, $ represents p b 0.05 compared to inhibitor alone, and & represents p b 0.05 compared tboth E2 and E2-BSA (Supplementary Fig. S7) reduced the effect of CTX
and taxol on caspase-3 activity, indicating that the anti-apoptotic effect
of E2 may require membrane activation of Gαs.(20 μM) caspase-3 activity is reduced by 10−8 M E2, whilewortmannin blocks this effect.
compared to the untreated control group while # represents p b 0.05 compared to 20 μM
o inhibitor and taxol.
Fig. 5. Role of LPA, PI3K, Ca++, and G-protein signaling in the anti-apoptotic effect of E2 in HCC38 cells. (A) Taxol-induced (20 μM) caspase-3 activity is reduced by 10−8 M E2, while the
LPAR1/3 antagonist, VPC32183S, does not allow E2 to block the effect of taxol. * represents p b 0.05 compared to the untreated control groupwhile # represents p b 0.05 compared to 20 μM
taxol and $ represents p b 0.05 compared to inhibitor alone. (B) Taxol-induced (20 μM) caspase-3 activity is reduced by LPA. * represents p b 0.05 compared to the untreated control
group while # represents p b 0.05 compared to 20 μM taxol. (C) Taxol-induced (20 μM) caspase-3 activity is reduced by 10−8 M E2, while the LY294002 does not allow E2 to block the
effect of taxol. * represents p b 0.05 compared to the untreated control group while # represents p b 0.05 compared to 20 μM taxol and $ represents p b 0.05 compared to inhibitor
alone. (D) Taxol-induced (20 μM) caspase-3 activity is reduced by the PI3K activator 740 Y-P. (E) Taxol-induced (20 μM) caspase-3 activity is reduced by 10−8 M E2, while thapsigargin
enhances caspase-3 activity alone and this is also reduced by E2. (F) Taxol-induced (20 μM) caspase-3 activity is reduced by 10−8 M E2, while pertussis toxin and cholera toxin both
enhance caspase-3 activity alone. The effect of CTX is reduced by E2. * represents p b 0.05 compared to the untreated control group while # represents p b 0.05 compared to 20 μM
taxol and $ represents p b 0.05 compared to inhibitor alone.
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HCC38 cells treatedwith 10−8 M E2 for 9min exhibited increased PM
localization of ERα36, as determined by densitometry analysis of western
blots (Supplementary Fig. S8), while cells pre-treated for 2 h with
tunicamycin (Tm) or 2-bromopalmitate (2-BP) did not (Fig. 6A). Cyclo-
heximide (CHM) had no effect on translocation of ERα36 to the mem-
brane in response to E2 (data not shown), nor did it alter E2-dependent
increases in PKC (Fig. 6B) or PLD (Fig. 6C). 2-Hydroxymyristic acid
(HMA) reduced translocation of ERα36 (Fig. 6A), but did not alter
E2-dependent PKC or PLD. In contrast, Tm and 2-BP blocked ERα36
translocation and the stimulatory effects of E2 on PKC and PLDindicating that palmitoylation played a role in these effects. In addition,
palmitoylation was required for the anti-apoptotic effect of E2. Tm
blocked the effect of E2 on taxol-induced caspase-3 activity (Fig. 6D)
as did 2-BP (Fig. 6E). Similar effects were observed in cells treated with
E2-BSA (Fig. 6F) indicating that a PM receptor was involved.
4. Discussion
This study examined amechanismbywhich E2 functions to promote
breast cancer cell survivability. Our approach used taxol as an agent to
induce apoptosis, and antibodies, inhibitors, and activators of proteins
involved in the hypothesized anti-apoptotic mechanism of action of
Fig. 6. Role of palmitoylation in the anti-apoptotic effect of E2 in HCC38 cells. (A)Western blot of PM fractions of HCC38 cells treatedwith 10−8 M E2 for 9min, pre-treatedwith 0.5mM2-
hydroxymyristic acid (HMA), which inhibits myristoylation, 30 μM tunicamycin (Tm), which inhibits N-glycosylation and palmitoylation, or 10 μM 2-bromopalmitate (2-BP), which in-
hibits palmitoylation, for 2 h indicates that ERα36 membrane-association occurs rapidly and is blocked by Tm and 2-BP. (B,C) Tm and 2-BP prevent the effect of 10−8 M E2 on (B) PKC
activation after 9 min and (C) PLD activation after 30 min. * represents p b 0.05 compared to corresponding untreated control. (D,E) Taxol-induced (20 μM) caspase-3 activity is reduced
by 10−8 M E2, while (D) Tm (30 μM) and (E) 2-BP (10 μM) block this effect. (F) Taxol-induced (20 μM) caspase-3 activity is reduced by 10−8 M E2-BSA, while Tm (30 μM) blocked this
effect. * represents p b 0.05 compared to the untreated control group while # represents p b 0.05 compared to 20 μM taxol and $ represents p b 0.05 compared to inhibitor (Tm or 2-BP)
alone. @ represents p b 0.05 compared to taxol and 2-BP alone.
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caspase-3 is a downstream regulator of taxol-induced apoptosis, and
we previously showed that membrane-associated E2 signaling abro-
gates the effect of taxol on caspase-3 activity [18]. While TUNEL is
ideal in measuring cell death as an indicator of DNA fragmentation
typical of apoptosis, we believe that caspase-3 is a more adequate
assessment of cell physiology. Taxol caused apoptosis in HCC38 cells
in a similarmanner to that seen in ER-positiveMCF7 and ZR-75-1 breast
cancer cells through activation of Bcl2 associated proteins, cytochrome-
C translocation, and caspase-3 activation [3]. While other forms of apo-
ptosis exist other than those functioning through caspase-signaling
[45], this study was based on previous work showing an antagonistic
role of E2 against caspase-dependent taxol-induced apoptosis [3].
HCC38 cells, which are thought to be triple-negative, do express
ERα36, an alternatively spliced variant of the traditional ERα [18]. E2
signaling promoted anti-apoptosis against taxol-induced caspase-3
activity. The ability of antibodies against ERα36 and ERα36 silencing
to prevent the anti-apoptotic effect of E2 against taxol in this study
proves that the anti-apoptotic effect is mediated speciﬁcally through
membrane-associated ERα36.
While results using only E2 do not speciﬁcally prove the role of a
membrane-mediate mechanism, our results using E2-BSA support the
role of amembrane receptor. Not only have our results using antibodies
against ERα36 implicate it as the membrane receptor responsible for
these effects, but membrane association is required for these effects,
as is seen with the results using inhibitors to palmitoylation. Because
the anti-apoptotic effect of E2 is through a non-genomic, membrane-
mediated mechanism that begins with E2/ERα36 interaction at the
PM, we hypothesized that dynamic palmitoylation by palmitoylacetyl-transferase (PAT) mediates the membrane effect of E2 through ERα36
against taxol-induced caspase-3 activity. As expected, due to several
previous studies indicating thatmembrane association of ERs, particularly
ERα66 and ERα46, occurs due to palmitoylation [42,43], the membrane
effect of E2 through ERα36 is also mediated via palmitoylation. The use
of 2-hydroxymyristic acid (HMA), which prevents myristoylation of pro-
teins, did not abolishmembrane association of ERα36. Ourwork using cy-
cloheximide (CHM), HMA, tunicamycin, and 2-bromopalmitate (2-BP),
indicates that membrane association of ERα36 can occur rapidly within
minutes of treatment with E2, suggesting that E2 itself promotes rapid
association of ERα36 with the PM via palmitoylation. Tunicamycin
(Tm), a known inhibitor of PAT, completely blocked the E2-inducedmem-
brane association of ERα36. However, Tm is also known to be a potent
inhibitor of N-glycosylation [42], indicating that it is not the most ideal
candidate for studying palmitoylation. Therefore, CHMwas used as a suit-
able control for this undesired effect of Tm, and CHMwas unable to block
the E2-induced PMassociation of ERα36. In addition,weused 2-BP to spe-
ciﬁcally inhibit PAT activity [44]. The effects of 2-BP were similar to those
seenwith Tm, andwith both inhibitors, we observed a reduction in rapid
membrane association of ERα36, an inhibitory effect on E2-induced PKC
and PLD activation, and complete abolishment of the anti-apoptotic effect
of E2. These results lead to the conclusion that the anti-apoptotic effect of
E2 occurs with rapid and dynamic palmitoylation of ERα36 leading to
membrane association of the receptor within minutes.
In addition, ERα36 contains a unique C-terminal exon, exon 9,which
codes for 27 amino acids of unknown function. Wang et al. hypothe-
sized that this exon contains a potential myristoylation sequence [21].
Therefore, we created ERα36 deletion mutants to determine if the
anti-apoptotic membrane effect of E2 is dependent on the presence of
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exogenous ERα36 and exon 9-deleted ERα36 expression plasmids. We
observed the requirement for exon 9 in the effect of E2 on PLD activity,
but the role of exon 9 in the effect of E2 against taxol-induced caspase-
3 was less clear. Because we observed an increase in caspase-3 activity
when we removed exon 9 without any other treatment, it is possible
that the removal of exon 9 alters the overall effect of ligand-
independent ERα36. Because our results indicate that palmitoylation
is a mechanism by which ERα36 translocates dynamically to the PM,
and HMA did not prevent the effect of E2, further studies are necessary
to determine if exon 9 is a target for palmitoylation of ERα36.
Previous resultswere not clear as to how E2 promotes anti-apoptosis
[3]. The vitamin-D3 metabolite, 24R,25-dihydroxyvitamin-D3, another
steroid hormone that activates PKC through a similar mechanism as
E2, has anti-apoptotic effects by activating PLD in chondrocytes [35].
Based on this, we investigated whether E2 can rapidly activate PLD in
breast cancer cells and found that E2 activated PC-PLD within 30 min,
which occurred speciﬁcally through membrane-associated ERα36.
Moreover, wortmannin blocked the effect of E2 on taxol-induced
caspase-3 activity, indicating that PLD activation mediates the anti-
apoptotic effect of E2 in breast cancer, particularly in TNBC cells.
While PC-PLDwas shown to play a role in the anti-apoptotic effect of
E2, neither PI-PLC nor PC-PLC appeared to be involved. Neither U73122
nor D609 abrogated the effect of E2; however, both blocked the effect of
taxol on caspase-3 activity, suggesting a possible role of PLC in taxol's
apoptotic mechanism. As Levin et al. showed that taxol induces apopto-
sis through a JNK-dependent mechanism [46], it is possible that JNK is
activated through a pathway requiring PLC. Other studies show that
JNK activation can occur through a PKC-associated pathway, explainingFig. 7. Proposed mechanism by which E2 promotes cancer cell survival. E2 signaling through
through a G-protein-PLC-PKC speciﬁc pathway and the anti-apoptotic effect through PLD-LPA
PKC via DAG and calcium-dependent PKC can also mediate anti-apoptosis.the effects of D609 and U73122, which inhibit PC-PLC and PI-PLC
respectively, on taxol-induced caspase-3 activity.
Due to its well-known role in anti-apoptotic pathways [47–49], we
hypothesized PI3K to be part of the pathway by which E2 exerts its
anti-apoptotic effect. Not only did LY294002, a speciﬁc inhibitor of
PI3K, block E2's anti-apoptotic effect against taxol, but also the PI3K
activator, 740 Y-P, alone prevented taxol's apoptotic effect. Similarly,
the addition of LPA, which is known to regulate anti-apoptosis through
a PI3K-Akt-dependent mechanism [35], prevented the effect of taxol on
cancer cell apoptosis. However, the use of VPC32183S, which inhibits
signaling of LPA via the LPA1 and LPA3 receptors [50], not only blocked
the E2 anti-apoptotic effect, but also appeared to block taxol's effect. Be-
cause this inhibitor is not speciﬁc to one isoform of the LPA receptor, it
may have multiple competing effects on LPA signaling. These effects
on taxol-induced apoptosis suggest that LPA signaling is a promiscuous
process that may have differential effects on apoptotic signaling path-
ways, and it may be that LPA signaling, while it appears to be a compo-
nent of the anti-apoptotic effect of E2, may also function in the pathway
by which taxol induces apoptosis.
We originally hypothesized that G-protein and intracellular calcium
signaling may also play a role in the anti-apoptotic effect of E2.
Thapsigargin, an inhibitor of endoplasmic reticulum-associated calcium
channels to block the inﬂux of calcium to the cytosol, alone caused a
marked increase in caspase-3 activity in HCC38. Although this effect
was reduced by the use of E2, it was not clear whether calcium involve-
ment in this anti-apoptotic effect of E2 was speciﬁcally through the
pathway that includes PLD. Interestingly, aswehave shown that PKCac-
tivity is important for themaintenance of cancer cell survival [18], these
results suggest that PLC-speciﬁc PKC activation, which requires calciummembrane-associated ERα36 activates two pathways, mediating the proliferative effect
-PI3K speciﬁc pathway. Cross-talk can occur between these pathways as PLD can activate
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cell proliferation, but may also crosstalk with the anti-apoptotic path-
way to block caspase-3. Similarly, we also observed that PTX and CTX,
inhibitors of G-protein signaling, also caused marked increases in
caspase-3 activity alone. Although the role of G-protein is unclear due
to these results, it is interesting to note that the rapid activation of
PKC in HCC38 cells occurs via Gαs activation. We can also suggest that
these effects of PTX and CTX may be due to attenuation of LPA receptor
signaling, which depends on G-protein function.While the effect of PTX
on caspase-3 activity was not abrogated by E2, the effect of CTX, which
speciﬁcally inhibits Gαs signaling, was reduced by E2, which is consis-
tent with the idea that PKC activation by E2 occurs by Gαs activation
[17] and is anti-apoptotic. Although further investigation into the role
of Gαs signaling in this pathway is necessary, the results suggest a
membrane-delimited role of ERα36 in the anti-apoptotic pathway of E2.
Based on the results of this study, along with previous work regard-
ing E2's non-genomic, membrane-mediated effects in HCC38 cells, we
have developed a working model for a mechanism by which E2
promotes TNBC cell survival, speciﬁcally through proliferative and
anti-apoptotic effects. Interaction of E2 with ERα36 on the PM leads to
a signaling cascade that begins with G-protein activation, speciﬁcally
Gαs, leading to activation of phosphatidylcholine-speciﬁc PLD (Fig. 7).
PLD then converts phosphatidylcholine (PC) to phosphatidic acid
(PA), which after conversion to lysophosphatidic acid (LPA) activates
LPA receptors, which promote activation of PI3K. PI3K then promotes
anti-apoptotic activity, which can prevent activation of a caspase signal-
ing cascade that ultimately leads to caspase-3 activation and apoptosis.
As taxol promotes caspase-3 activation through a mechanism detailed
by Levin et al. [3], which includes JNK phosphorylation and cytochrome
C release from the mitochondria, E2's inhibitory effect on caspase-3
activity counteracts the pro-apoptotic effect of taxol. At the same time,
the activation of signaling through ERα36 can also promote PKC activa-
tion through PLC, diacylglycerol (DAG), and inositol trisphosphate (IP3)
[17,18]. PLD can also further activate PKC, indicating cross talk between
diverging pathways that are simultaneously activated by E2 at the PM
[17,39]. This rapid activation of PKC can lead to proliferative pathways
including MAP kinase signaling. Our previous mechanism of action of
E2 signaling through ERα36 leading to cell proliferation together with
our current proposedmodel of anti-apoptosis suggests a combined del-
eterious effect of E2 signaling in breast cancer cells [17,18].While E2 pro-
motes proliferation through ERα36, it can also promote anti-apoptosis
against chemotherapeutics, protecting cancer cells from therapy, while
promoting tumor growth.
Histological results examining ERα36 in tumors have shown better
prognosis in patients with membrane localization of ERα36 [51].
While this would initially appear to be a divergent result towhat we re-
port in the current study, we cannot control for external effects in these
patients, such as treatments to which our cells are not exposed in vitro.
Perhaps better prognosis in these patients illustrates a possible role of
ERα36 as an ideal treatment target. It is possible that tamoxifen,
which can inhibit protein kinase C and thus the proliferative pathway
of E2, can act through ERα36 or ERα36-dependent signaling pathways,
and this may result in a better prognosis. If this is true, this just further
demonstrates the value of ERα36 as a novel target.
5. Conclusion
This study provides a working model for a mechanism of
membrane-associated E2 signaling in TNBC through ERα36. We
previously showed that rapid activation of PKC is mediated by
PM-associated ERα36 leading to cancer cell proliferation. Here we
show that activation of ERα36 by E2 also leads to activation of anti-
apoptosis, involving PC-PLD, LPA, and PI3K. Crosstalk can also occur
due to the ability of PLD to activate PKC through a DAG-dependent
mechanism, with PKC able to promote anti-apoptosis. The role of
ERα36 in this pathway, and the fact that ERα36 mediates this effectfrom the PM, suggests that ERα36may be a suitable target for diagnosis
and treatment of breast cancer. Perhaps ERα36 speciﬁc monoclonal
antibodies would provide another avenue to more robustly target and
kill breast cancer cells overexpressing the receptor. In theory, targeting
of ERα36 would prevent the anti-apoptotic effect of E2 and thus provide
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